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SCIENTIFIC OPINION 
Scientific Opinion on the safety and efficacy of Coxiril
® (diclazuril) as a 
feed additive for turkeys for fattening
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Coxiril
®,  containing  0.5 %  diclazuril,  is  intended  for  the  control  of  coccidiosis  in  turkeys  for  fattening  at 
concentrations between 0.8 and 1.2 mg diclazuril/kg complete feed. The highest proposed use level (1.2 mg 
diclazuril/kg feed) is considered safe for turkeys for fattening. Diclazuril has no substantial antibacterial activity. 
Diclazuril from Coxiril
® is considered toxicologically equivalent to the other currently authorised diclazuril. The 
use of Coxiril
® at the highest proposed use level of 1.2 mg diclazuril/kg complete feed in turkeys for fattening is 
safe for the consumer since Maximum Residue Limits are not exceeded. Coxiril
® is considered non-irritant to 
eyes and skin. It is not a potential skin sensitiser. User exposure to Coxiril
®, as a result of normal handling, is 
unlikely to cause respiratory or systemic toxicity. Based on a Phase I assessment, the use of diclazuril in turkeys 
for fattening at the high use level does not pose a risk to the environment. Diclazuril from Coxiril
® has the 
potential to control coccidiosis in turkeys for fattening at a minimum concentration of 0.8 mg/kg complete feed. 
This conclusion is derived from literature data, and from recent studies performed with Coxiril
®. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy  of  Coxiril
®  (diclazuril)  in  turkeys  for  fattening.  Coxiril
®,  containing  0.5 %  diclazuril,  is 
intended for the control of coccidiosis in turkeys for fattening at concentrations between 0.8  and 
1.2 mg diclazuril/kg complete feed. 
The highest proposed use level (1.2 mg diclazuril/kg feed) is considered safe for turkeys for fattening. 
None of the parameters measured in the tolerance study showed an adverse effect of the 12-fold use 
level of diclazuril. However, the tolerance study showed a certain weakness particularly due to a low 
number of blood samples per treatment and sex. Diclazuril has no substantial antibacterial activity. 
Diclazuril from Coxiril
® is considered toxicologically equivalent to the other currently authorised 
diclazuril since the specifications of the European Pharmacopoeia are respected. A residue study with 
Coxiril
® in turkeys for fattening demonstrated compliance with  the Maximum Residue Limits for 
diclazuril  without  applying  a  withdrawal  period.  Consequently,  Coxiril
®  used  at  the  highest  dose 
proposed (1.2 mg diclazuril/kg complete feed) is safe for the consumer. 
Coxiril
® is considered non-irritant to eyes and skin. It is not a potential skin sensitiser. User exposure 
to Coxiril
®, as a result of normal handling, is unlikely to cause respiratory or systemic toxicity. 
The use of diclazuril in turkeys for fattening at the highest use level does not pose a risk to the 
environment. 
Diclazuril from Coxiril
® has the potential to control coccidiosis in turkeys for fattening at a minimum 
concentration of 0.8 mg/kg complete feed. This conclusion is derived from literature data, and from 
recent studies performed with Coxiril
®. Coxiril
® (diclazuril) for turkeys for fattening 
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BACKGROUND 
Regulation (EC) No 1831/2003
4 establishes the rules governing the European Union authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The European Commission received a request from the company Huvepharma N.V.
5 for authorisation 
of the product Coxiril
® (diclazuril) when used as a feed additive for turkeys for fattening (category: 
coccidiostats and histomonostats) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application  to  the  European  Food  Safety  Authority  (EFSA)  as  an  application  under  Article  4(1) 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from  the 
applicant  the  technical  dossier  in  support  of  this  application.
6 According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 7 December 2012. 
The additive Coxiril
® (diclazuril) is not authorised in the European Union. 
The product Clinacox
® 0.5 % containing the same active substance (diclazuril) has been authorised for 
ten  years  for  use  in  rabbits  (authorisation  until  24  October  2018),
7 in  chickens  for  fattening 
(authorisation until 23 December 2020),
8 in chickens reared for laying (authorisation until 2 August 
2023),
9 in turkeys for fattening (authorisation until 26 September 2021),
10 and in guinea fowl 
(authorisation until 16 March 2021).
11 
The MRLs are part of the respective authorisations of Clinacox
® 0.5 % for chickens
12 and turkeys for 
fattening
13  and  for  guinea  fowl.
14  The  values  proposed  have  been  enforced  at  the  EU  level 
(Commission Regulation (EC) No 976/2008).
15 Commission Implementing Regulation (EU) No 
115/2013 introduced MRLs for poultry (liver, kidney, muscle, skin/fat).
16 
                                                        
4  Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5  Huvepharma NV, Uitbreidingstraat 80, Antwerp, Belgium. 
6  EFSA Dossier reference: FAD-2012-0036. 
7  Commission Regulation (EC) No 971/2008 of 3 October 2008 concerning a new use of a coccidiostat as additive in 
feedingstuffs. OJ L 265, 4.10.2008, p. 3. Corrigendum EN in OJ L 267, 8.10.2008, p. 32. 
8  Commission Regulation (EU) No 1118/2010 of 2 December 2010 concerning the authorisation of diclazuril as feed 
additive for chickens for fattening (holder of the authorisation Janssen Pharmaceutica NV) and amending Regulation (EC) 
No 2430/1999. OJ L 317, 3.12.2010, p. 5. 
9  Commission Implementing Regulation (EU) No 667/2013 of 12 July 2013 concerning the authorisation of diclazuril as 
feed additive for chickens reared for laying (holder of the authorisation Eli Lily and Company Ltd) and repealing 
Regulation (EC) No 162/2003. OJ L 192, 13.7.2013, p. 35.  
10 Commission Implementing Regulation (EU) No 888/2011 of 5 September 2011 concerning the authorisation of diclazuril 
as feed additive for turkeys for fattening (holder of the authorisation Janssen Pharmaceutica NV) and amending Regulation 
(EC) No 2430/1999. OJ L 229, 6.9.2011, p. 9. 
11 Commission Regulation (EU) No 169/2011 of 23 February 2011 concerning the authorisation of diclazuril as feed additive 
for guinea fowls (holder of the authorisation Janssen Pharmaceutica NV). OJ L 49, 24.2.2011, p. 6. 
12 OJ L 317, 3.12.2010, p. 5. 
13 OJ L 229, 6.9.2011, p. 9. 
14 OJ L 49, 24.2.2011, p. 6. 
15 Commission Regulation (EC) No 976/2008 of 6 October 2008 amending Regulations (EC) No 2430/1999, (EC) No 
162/2003 as regards the terms of the authorisation of the feed additive ―Clinacox‖, belonging to the group of coccidiostats 
and other medicinal substances.OJ L 266, 7.10.2008, p. 3. 
16 Commission Implementing Regulation (EU) No 115/2013 of 8 February 2013 amending the Annex to Regulation (EU) No 
37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of 
animal origin, as regard the substance diclazuril. OJ L 38, 9.3.2013, p. 11. Coxiril
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The Scientific Committee on Animal Nutrition (SCAN) issued an opinion on the use of diclazuril in 
feedingstuffs for chickens for fattening (EC, 1991) and an opinion on extension of use of diclazuril to 
the feedingstuffs for chickens reared for laying (EC, 1997). 
The additive Coxiril
® (diclazuril) for turkeys for fattening has never been assessed by EFSA. 
The European Food Safety Authority (EFSA) issued an opinion on the Maximum Residue Limits 
(MRLs) for the additive Clinacox
® 0.5 % containing the same active substance (diclazuril) for turkeys 
for fattening, chickens for fattening and chickens reared for laying (EFSA, 2007a). This opinion was 
updated by EFSA on 16 April 2008 (EFSA, 2008a). On 23 June 2010 the EFSA adopted an opinion on 
the safety and efficacy of Clinacox
® 0.5 % for chickens for fattening (EFSA FEEDAP Panel, 2010a), 
on 5 October 2010 an opinion on the safety and efficacy of Clinacox
® 0.5 % for guinea fowl (EFSA 
FEEDAP Panel, 2010b) and on 16 March 2011 an opinion on the safety and efficacy of Clinacox
® 
0.5 % for turkeys for fattening (EFSA FEEDAP Panel, 2011a). Finally, an opinion on re-evaluation of 
safety and efficacy of Clinacox
® 0.5 % for chickens reared for laying was adopted in 2013 (EFSA 
FEEADP Panel, 2013). In 2014 EFSA adopted an opinion on the safety and efficacy of Coxiril
® for 
chickens for fattening (EFSA FEEDAP Panel, 2014). 
EFSA issued an opinion on the safety and efficacy of Clinacox
® 0.5 % based on diclazuril for rabbits 
for fattening and breeding (EFSA, 2007b), then updated in 2008 (EFSA, 2008b). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Coxiril
® (diclazuril), when used under the conditions described in Table 1. Coxiril
® (diclazuril) for turkeys for fattening 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive   Diclazuril 
Registration number/EC 
No/No (if appropriate)  Not applicable 
Category(-ies) of additive  coccidiostat 
Functional group(s) of additive  coccidiostat 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Additive composition 
Diclazuril: 5.0g/kg 
Starch: binding agent 
Wheat meal: carrier 
Calcium carbonate: carrier 
 
International Non-
proprietary Name:  
Diclazuril. 
 
Chemical name: 
(RS)-(-4-Chlorophenyl)[2,6-
dichloro-4-(3,5-dioxo-4,5-
dihydro-1,2,4-triazin-2(3H)-
yl)phenyl]acetonitrile. 
 
CAS number:  
[101831-37-2] 
C17H9Cl3N4O2 
 
 
Impurity D: ≤ 0.1 % 
 
Any other single 
impurity: ≤ 0.5 % 
 
Total impurities: 
 ≤ 1.5 % 
 
 
 
Feed: reversed phase 
HPLC with UV detection 
 
Poultry tissues:  
LC MS/MS 
 
 
 
Trade name (if appropriate)  Coxiril 
Name of the holder of 
authorisation (if appropriate)  Huvepharma NV 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  mg/kg of complete feedingstuffs 
Turkeys for 
fattening  /  0.8  1.2  no withdrawal 
period needed 
 Coxiril
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Other provisions and additional requirements for the labeling 
Specific conditions or restrictions for 
use (if appropriate)  NA 
Specific conditions or restrictions for 
handling (if appropriate) 
Wear suitable protective clothing, gloves and eye/face protection. In 
case of insufficient ventilation in the premise, wear suitable 
respiratory equipment.  
 
Post-market monitoring  
(if appropriate)  NA 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
NA 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
diclazuril  poultry 
Skin+fat 
Muscle 
Liver 
Kidney 
500 μg/kg 
500 μg/kg 
1500 μg/kg 
1000 μg/kg Coxiril
® (diclazuril) for turkeys for fattening 
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ASSESSMENT 
1.  Introduction 
The  current  application  concerns  the  authorisation  of  Coxiril
®,  containing  the  active  substance 
diclazuril, for use as a coccidiostat in turkeys for fattening. This additive is not authorised in the 
European  Union.  However,  the  same  active  substance,  when  contained  in  the  additive  Clinacox
® 
0.5 %, is currently authorised for use in chickens for fattening,
17 chickens reared for laying,
18 turkeys 
for fattening,
19 guinea fowl
20 and rabbits.
21 
The European Food Safety Authority (EFSA) has adopted several opinions on the safety and efficacy 
of Clinacox
®  0.5 %  for  rabbits  for  fattening  and  breeding  (EFSA,  2007b,  2008b),  chickens  for 
fattening (EFSA FEEDAP Panel, 2010a), guinea fowl (EFSA FEEDAP Panel, 2010b), turkeys for 
fattening  (EFSA  FEEDAP  Panel,  2011a)  and  chickens  reared  for  laying  (EFSA  FEEDAP  Panel, 
2013). In 2014, EFSA adopted an opinion on the safety and efficacy of Coxiril
® for chickens for 
fattening (EFSA FEEDAP Panel, 2014). 
In 2008, EFSA issued an opinion on Maximum Residue Limits (MRLs) for diclazuril when used in 
turkeys for fattening, chickens for fattening and chickens reared for laying. The MRLs are enforced by 
Commission  Regulation  (EC)  No  976/2008.
22  Commission  Implementing  Regulation  (EU )  No 
115/2013 introduced MRLs for poultry (liver, kidney, muscle, skin/fat).
23 
2.  Characterisation 
The identity of the additive, the characterisation of the active substance and the manufacturing process 
have been reviewed by the FEEDAP Panel (EFSA FEEDAP Panel, 2014). The conditions of use 
proposed  for  turkeys  for  fattening  are  identical  to  those  described  for  chickens  for  fattening,  i.e. 
Coxiril
® is intended for prevention of coccidiosis in turkeys for fattening at a dose range of 0.8 to 
1.2 mg diclazuril/kg complete feed. No withdrawal period is proposed by the applicant. 
2.1.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
The EURL considered that the conclusions and recommendations reached in the previous assessment 
are valid and applicable for the current application.
24 
3.  Safety 
3.1.  Safety for the target species 
3.1.1.  Tolerance study in turkeys for fattening 
A tolerance study
25 with Coxiril
® was carried out in 160 one-day-old turkeys for fattening (Hybrid 
Grademaker)  for  eight  weeks.  The  diclazuril  concentrations  were  0 mg/kg  (control),  1.2 mg/kg 
(highest dose), 3.6 mg/kg (three-fold the highest dose) and 14.4 mg/kg (12-fold the highest dose). The 
intended concentrations in mash feed (starter diet for the first two weeks, grower diet until completion) 
were analytically confirmed. Four replicates of male and four replicates of female birds were included 
                                                        
17 OJ L 317, 3.12.2010, p. 5. 
18 OJ L 192, 13.7.2013, p. 35 
19 OJ L 229, 6.9.2011, p. 9. 
20 OJ L 46, 24.2.2011, p. 6. 
21 OJ L 265, 4.10.2008, p. 3. 
22 OJ L 266, 7.10.2008, p. 3. 
23 OJ L 38, 9.3.2013, p. 11. 
24 The full report is available on the EURL website: http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep -FAD-
2012-0017.pdf 
25 Technical dossier/Section III/Annex 1. Coxiril
® (diclazuril) for turkeys for fattening 
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in each treatment, and the final number of animals per replicate was five (plus two spare birds, which 
were removed after one week). The diets consisted mainly of soybean meal, wheat and wheat feed. 
The crude protein content of the starter and the grower diets was calculated to be 28.2 % and 26.5 %, 
and the total metabolisable energy as 12.2 and 12.0 MJ/kg, respectively.
26 
Body weight and feed intake were measured weekly. On day 55, blood samples were taken from one 
bird per replicate and were analysed for haematology and routine clinical chemistry.
27 At termination 
of the study (day 56/57), one bird per replicate was killed and necropsied; organs were weighed (heart, 
liver, kidneys and spleen) and examined macroscopically and microscopically.
28 No information was 
provided on how this bird was selected. Statistical evaluation started with a Bartlett‘s test for variance 
homogeneity; depending on the outcome, this was followed by either a parametric test (Williams‘ test 
with Dunnett‘s test for group differences) or a non-parametric test (Shirley‘s test). Organ weight was 
statistically studied by covariance analysis using body weight as a covariate. The statistical procedure 
was  applied  separately  to  both  sexes  and  to  the  data  of  individuals  (except  feed  consumption). 
Following a request from the FEEDAP Panel, the statistical analysis was repeated using the replicate 
as the experimental unit for all zootechnical parameters.
29 However, group size for haematological and 
plasma clinical chemistry was small (four birds per gender and treatment). 
Mortality (including culled birds) was low (3 out of a total of 160 birds). One bird died in the use level 
group and one in the intermediate-dose level group; one bird was euthanised in the control group. 
Total body weight gain (average 3  706 g), feed consumption (average 158  g/bird) and  feed-to-gain 
ratio were not statistically different between the treatments. It sh ould be noted that feed intake and 
body weight gain might be not optimal owing to the use of a mash instead a pelleted diet. 
Haematological results revealed no treatment-related effects with the exception of a significant , but 
not dose-related, reduction in monocytes in all treated groups. No significant changes were seen in the 
clinical blood chemistry parameters, except for a statistically lower creatinine level in the high -dose 
group. There were no treatment-related relevant findings regarding absolute and body weight-adjusted 
organ weights, organ macropathology or histopathology. 
3.1.2.  Microbial studies 
Diclazuril is devoid of antimicrobial activity against a range of fungi and bacteria, including several 
pathogens (Renshaw, 2013). 
Data provided by the applicant on the minimum inhibitory concentration values measured for strains 
of  Escherichia  coli  (ATCC  25922),  Pseudomonas  aeruginosa  (ATCC  27853),  Bacillus  subtilis 
(ATCC 6633), Enterococcus faecalis (ATCC 29212) and Staphylococcus aureus (ATCC 25923), all 
of which are above 64 mg/L, may be used as partial confirmation of the above statement.
30 
3.1.3.  Conclusions on the safety for turkeys for fattening 
The value of the tolerance study is somewhat limited owing to the low number of replicates/animals 
per treatment and sex. However, none of the endpoints measured showed a relevant adverse treatment-
related  effect  of  diclazuril  at  12-fold  the  use  level.  The  highest  proposed  use  level  (1.2 mg 
diclazuril/kg  feed)  is  considered  safe  for  turkeys  for  fattening.  Diclazuril  has  no  substantial 
                                                        
26 Supplementary information. February 2014. Reference 1. 
27 Haematocrit, haemoglobin concentration, erythrocyte count, mean corpuscular haemoglobin, mean corpuscular volume , 
mean corpuscular haemoglobin concentration, total white cell count, differential white blood cell count: heterophils, 
lymphocytes, basophils, eosinophils, monocytes, thrombocytes, alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase,  lactate  dehydrogenase,  cr eatine  kinase,  bilirubin,  bile  acids,  uric  acid,  creatinine,  glucose,  total 
cholesterol, sodium, potassium, chloride, calcium, phosphorus, magnesium, total protein and albumin. 
28 Caeca, colon, duodenum, ileum, heart, kidneys, liver, lungs and spleen. 
29 Supplementary information. February 2014. Reference 2. 
30 Technical dossier/Section III/Annex 2. Coxiril
® (diclazuril) for turkeys for fattening 
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antibacterial activity and, consequently, no microbial risk to the target species or induction of cross-
resistance to clinically relevant antibiotics is expected. 
3.2.  Safety for the consumer 
Commission Regulation (EC) No 976/2008 has set the first MRLs for diclazuril used as a feed additive 
for chickens for fattening, chickens reared for laying and turkeys for fattening. The latest Commission 
Implementing Regulation (EU) No 115/2013 extends the same values to all poultry, also covering the 
use of diclazuril for veterinary purposes. These values are 1 500  g/kg wet liver, 1 000  g/kg wet 
kidney and 500  g/kg wet muscle and skin/fat. 
The Regulations
31 concerning the use of diclazuril as a feed additive for different poultry species and 
categories refer to diclazuril of another applicant (Clinacox
® 0.5 %). In these Regulations, diclazuril is 
specified by thresholds for substance-related impurities, which are quoted through in-house identifiers. 
The qualitative and quantitative nature of these impurities fully complies with the impurities specified, 
and has been analytically confirmed for the diclazuril under application (EFSA FEEDAP Panel, 2014; 
see also section 2.4 and Appendix A). Both specifications comply with the European Pharmacopoeia 
(Ph. Eur. 7, 2011). 
The  FEEDAP  Panel  considers  that  diclazuril  from  Coxiril
®  is  chemically  and,  consequently, 
toxicologically  equivalent to  diclazuril from  the  authorised  additive. Therefore,  the  safety  for  the 
consumer of the diclazuril under application can be assessed without additional data on metabolism 
and toxicology. 
However,  since  the  composition  of  the  additive  Coxiril
®  is  different  to  that  of  Clinacox
®  0.5 % 
(although both contain 0.5 % diclazuril) and the proposed maximum dose of diclazuril from Coxiril
® 
is higher (1.2 vs. 1.0 mg/kg complete feed), the compliance of diclazuril residues from Coxiril
® with 
the MRLs should be demonstrated. 
In a residue study,
32 one-day-old turkeys were fed a complete feed supplemented with Coxiril
® at the 
target dose of 1.2 mg diclazuril/kg feed (1.36 mg/kg analysed in finisher feed) for 16 weeks. The 
marker residue depletion was followed. Birds (three males and three females per withdrawal time 
point) were slaughtered 0, 3, 6 and 24 hours after withdrawal of the supplemented feed and tissues 
sampled. Diclazuril residue concentrations were determined in the tissues using a validated liquid 
chromatography–tandem  mass  spectrometry  (LC-MS/MS)  method  with  a  limit  of  quantification 
(LOQ) of 50 μg/kg in liver, kidney, muscle and skin/fat (Table 2). 
Table 2:   Tissue residue kinetics of diclazuril in turkeys administered Coxiril
® (1.2 mg diclazuril/kg 
feed) for 16 weeks  
  Diclazuril residues (mg/kg wet tissue) 
(a) 
Withdrawal 
period (h) 
Liver  Kidney  Muscle  Skin/fat 
0  0.377 ± 0.095 (0.568) 
(b)  0.297 ± 0.061 
(0.398) 
0.057 ± 0.002 
(0.061) 
0.100 ± 0.025 
(0.149) 
3  0.402 ± 0.032 (0.466)  0.314 ± 0.024 
(0.362) 
0.061 ± 0.006 
(0.073) 
0.107 ± 0.016 
(0.139) 
6  0.653 ± 0.102 (0.857)  0.637 ± 0.064 
(0.765) 
0.061 ± 0.008 
(0.077) 
0.151 ± 0.014 
(0.179) 
24  0.310 ± 0.042 (0.394)  0.265 ± 0.031 
(0.327) 
0.056 ± 0.003 
(0.062) 
0.087 ± 0.009 
(0.105) 
(a):  Average values ± standard deviation (SD) of three males and three females per withdrawal time point. 
(b):  Average value + 2 SD. 
                                                        
31 OJ L 266, 7.10.2008, p. 3; OJ L 317, 3.12.2010, p. 5; OJ L 192, 13.7.2013, p. 35; OJ L 229, 6.9.2011, p. 9; OJ L 49, 
24.2.2011, p. 6. 
32 Technical dossier/Section III/Annex 5. Coxiril
® (diclazuril) for turkeys for fattening 
 
EFSA Journal 2014;12(6):3729  11 
All values measured in tissues at any withdrawal time were below the corresponding MRLs. It is 
therefore concluded that the use of Coxiril
® in diets for turkeys for fattening at the maximum proposed 
concentration complies with the MRLs. No withdrawal time is required. 
The FEEDAP Panel concludes that the use of diclazuril from Coxiril
® at the maximum concentration 
of 1.2 mg/kg feed for turkeys for fattening does not raise concerns for the consumer. 
3.3.  Safety for the user 
Data  submitted  in  the  dossier  for  chickens  for  fattening  are  the  same  as  data  provided  in  the 
application  for  turkeys  for  fattening.  The  FEEDAP  Panel  has  already  assessed  these  data  (EFSA 
FEEDAP Panel, 2014) and concluded: ―Coxiril
® is considered as non-irritant to eyes and skin. It is 
not a potential skin sensitiser. User inhalation exposure to Coxiril
®, as a result of normal handling, is 
unlikely to cause respiratory or systemic toxicity.‖ 
3.4.  Safety for the environment 
Predicted environmental concentrations (PECs) were calculated for turkeys for fattening receiving a 
dose of 1.2 mg diclazuril/kg feed in accordance with the technical guidance for assessing the safety of 
feed additives for the environment (EFSA, 2008c). This yielded a PECsoil value of 5.6 µg/kg and a 
PECgroundwater value of 0.06 µg/L. 
The applicant provided the following information on physical/chemical properties: molecular weight 
407.64 g/mol, water solubility 10 µg/L, vapour pressure 1.21   10
–22 Pa and dissociation constant 5.9. 
The solubility of diclazuril increases from 0.0026 mg/L at pH 5 to 1.4 mg/L at pH 9. This strong pH 
dependence indicates the formation of soluble ions. This makes the sorption more complicated than 
that of a simple neutral molecule. Therefore, the lowest Koc (Freundlich) value should be selected as 
the most conservative assessment instead of a geometric mean value. 
Sorption studies with a radiolabelled diclazuril in 0.01 M calcium chloride in five soils with a pH 
range from 5 to 7 did not indicate clear pH dependence.
33 The lowest Koc (Freundlich) selected from 
these  soils  is  4 986 mL/g  with  a  1/n  of  0.818,  corresponding  to  the  soil  with  a  pH 5.1,  a  cation 
exchange capacity of 4.3 meq/100 g and a total organic carbon content of 0.65 %. 
Since the trigger values of 10 μg/kg for PECsoil and 0.1 μg/L for PECgroundwater are not exceeded, a 
Phase II assessment is not necessary. 
Using diclazuril from Coxiril
® in turkeys for fattening at the highest proposed feed concentration 
would not pose a risk to the environment. 
4.  Efficacy 
For coccidiostats, the efficacy data should derive from three types of target animal experiments: (1) 
screening for response using artificial single and mixed infections; (2) natural/artificial infection to 
simulate use conditions (e.g. floor pen studies with poultry), with at least one of the locations being in 
the EU; and (3) actual use conditions in field trials, all of which should have been carried out in the 
EU within the last five years. 
Sensitivity tests could replace field trials, provided they follow the criteria mentioned in the guidance 
document on coccidiostats and histomonostats (EFSA FEEDAP Panel, 2011b).
34 
                                                        
33 Supplementary information/January 2014. 
34 The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostat s and histomonostats (EFSA, 
2011b) that studies with artificial infection would be pr eferred over field trials due to their inherent weaknesses.  These 
short-term studies should use field strains of  Eimeria recently confirmed as pathogenic/resistant by a sensitivity test or 
recognised problems in the poultry operation (confirmed by veterinary certificate). The Eimeria field strains should ideally 
undergo one, but in any case not more than two, passage(s) before use in such trials. Coxiril
® (diclazuril) for turkeys for fattening 
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4.1.  Battery and floor pen trials with artificial single and mixed Eimeria infections 
To demonstrate the effect of diclazuril in battery and floor pen trials with turkeys for fattening, the 
applicant  submitted  three  studies  published  by  Vanparijs  et  al.  (1989a,  b,  1990)  performed  with 
diclazuril from Clinacox
®. 
A dose titration study in turkeys (Vanparijs et al., 1989a) indicated that diclazuril at dosages of 0.5 to 
2 mg/kg  feed  was  highly  active  against  the  three  major  pathogenic  species—E.  adenoides,  E. 
gallopavonis and E. meleagrimitis—and effective in terms of reducing lesions, abnormal droppings 
and oocyst shedding. Similar results were observed for E. dispersa (Vanparijs et al., 1989b). 
One floor pen trial (Vanparijs et al., 1990) in which turkeys were artificially infected via feed with 
E. adenoides, E. gallopavonis and E. meleagrimitis demonstrated that diclazuril, at dose levels of 0.5 
and 1 mg/kg, completely prevented lesions and oocyst excretion and improved body weight gain and 
feed-to-gain ratio. 
4.2.  Floor pen studies with diclazuril from Coxiril
® 
In study 1, performed in 2011
35 over 12 weeks, 918 ‗BIG 7‘ one-day-old male turkeys were randomly 
allocated  to  an  infected  treated  (IT,  intended  concentration  0.8  mg/kg,  analysed  0.68–0.93 mg 
diclazuril/kg feed) group, an infected untreated control (IUC) group or an uninfected untreated control 
(UUC) group (27 pens with 34 animals). On day 15, six birds (seeder birds) from both the IT and IUC 
groups  were  infected  with  a  mixture  of  Eimeria  species  (E.  meleagrimitis,  E.  adenoides  and 
E. dispersa) isolated from a recent field sample. A total of 32 birds died during the experiment (UUC, 
9; IUC, 16; and IT, 7). The average body weight was similar in the three groups during the first four 
weeks of the study. Overall, the feed-to-gain ratio was significantly better in the IT group (UUC, 2.32; 
IUC, 2.32; and IT, 2.25) owing to a reduced feed intake (UUC, 290 g; IUC, 288 g; IT, 280 g), while 
maintaining  the  daily  gain  (UUC,  10 630 g/bird;  IUC,  10 458 g/bird;  and  IT,  10 557 g/bird).  The 
oocyst counts per gram faeces (OPGs) on day 21 (i.e. six days after inoculation) were 1 log lower in 
the IT group than in the IUC group. On days 28 and 35, the OPG results were similar in the IUC and 
IT  groups.  By  day  42–49,  oocyst  excretion  had  decreased  to  almost  zero.  Some  excretion  was 
observed in the UUC group by day 42–49. Lesion scores were rather mild and similar in the IUC and 
IT groups. 
In study 2, performed in 2012
36 over 85 days, 512 ‗BUT T9‘ one-day-old male turkeys were randomly 
allocated to an infected treated (intended concentration 0.8 mg/kg, analysed 0.6–0.8 mg diclazuril/kg 
feed) group or an untreated group (16 pens with 32 animals). The infection was natural and therefore 
no experimental inoculation was performed. Four animals died during the course of the treatment: one 
from the treated group and three from the untreated group. No significant differences were observed in 
any  of  the  zootechnical  parameters  (body  weight,  feed-to-gain  ratio).  Peak  oocyst  excretion  was 
observed on day 22, but no differences were observed between groups, and after this time point oocyst 
excretion decreased in both groups. Lesion scores were mild and similar in both groups, although 
lesion scores of 2 were observed only in the unsupplemented group. This study was not considered 
further. 
In study 3, performed in 2011
37 over 12 weeks, 360 male ‗BUT8‘ one-day-old turkeys were randomly 
allocated to an UUC group, an IUC group or an IT group (intended concentration 0.8 mg/kg, analysed 
0.71–0.76 mg diclazuril/kg) (30 floor pens, 12 birds/pen). On day 14, birds in the IUC and IT groups 
were  inoculated  with  an  inoculum  based  on  a  recent  field  isolate  from  France  containing 
E. meleagrimitis, E. adenoides and E. dispersa. Overall mortality was low (3.1 %). During the acute 
infection (days 14–28), mortality was significantly higher in the IUC  group than in the IT group 
(4.2 % vs. 0 %). Coxiril
® significantly improved the overall feed-to-gain ratio (1.95) compared with 
                                                        
35 Technical dossier/Section IV/Annex 4. 
36 Technical dossier/Section IV/Annex 5. 
37 Technical dossier/Section IV/Annex 6. Coxiril
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the IUC group (2.05). Additionally, the IT group exhibited similar body weight gain, feed intake and 
feed-to-gain ratio to the UUC turkeys. On days 7 and 14 (before infection), no oocysts were found in 
the excreta of any of the treatment groups. The highest OPGs were observed on day 21. IT turkeys 
excreted significantly fewer E. meleagrimitis and E. dispersa oocysts than the IUC turkeys. From day 
28 to day 63, no significant differences were found in total OPGs between the three treatments. From 
day 49 until the end of the study, OPGs were very low in all treatment groups. 
In study 4, performed in 2013,
38 600 one-day-old male turkeys (Converter hybrid) w ere randomly 
allocated to three groups, an IT  group (0.68–0.83 mg diclazuril/kg feed), an IUC group or an UUC 
group (eight pens/group with 25 animals each). On day 16 of the 12-week study, one bird from each 
pen allocated to the infected groups (IUC and IT) was inoculated with a mixture of Eimeria species 
(E. meleagrimitis, E. adenoides and E. dispersa sporulated oocysts) isolated from a recent field sample 
(2013). The overall mortality was high: 17.3 % in the Coxiril
® (IT) group and 16.5 % in the IUC 
group. Both values were significantly higher than in the UUC group (6.2 %). Initially, the Eimeria 
infection caused a severe growth depression (body weight gain on day 33, 958 g/bird and 911 g/bird 
for  the  IT  and  the  IUC  groups,  respectively,  vs.  1 312 g/bird  in  the  UUC  group).  The  growth 
depression disappeared, statistically, on day 44 for the IT group. There were no differences in final 
body weight among the three groups. On day 27, no oocysts were detected in faecal samples from the 
UUC group. The total OPG count of the IUC and IT groups was found to be significantly higher than 
in the UUC group, without a significant difference between the IUC and IT groups. On day 33, all 
pens  of  the  UUC  group  were  infected.  On  day  44,  overall  oocyst  shedding  was  found  to  be 
significantly higher in the IUC groups than in the UUC and IT groups. There was no significant 
difference in total OPG count between the UUC and IT groups. Intestinal lesion score was measured 
in three birds from each pen after necropsy (seeder birds on day 21). No differences in the total lesion 
scores between the groups were observed at day 21. On day 33, total intestinal lesion scores of animals 
were found to be significantly higher in the IUC and IT groups than in the UUC group. There was no 
significant difference in total intestinal lesion scores between the IUC and IT groups. Intestinal lesion 
scores for E. meleagrimitis were found to be higher in the IUC group than in the IT group, but this 
difference was not statistically significant. There was no significant difference in average lesion scores 
for E. adenoides between infected groups (IUC and IT). 
4.3.  Efficacy studies under field conditions - sensitivity tests 
Three sensitivity tests were performed following the same experimental design as those described in 
the previous section, all of them conducted in 2012. In each trial, 108 ‗BIG 9‘ male turkeys (18 pens 
of six 13-day-old birds) were randomly allocated to an UUC group, an IUC group or an IT group 
(intended concentration diclazuril 0.8 mg/kg, analysed 0.58–0.60 mg diclazuril/kg). At the age of 16 
days,  birds  from  the  IUC  and  IT  groups  were  inoculated  with  recent  field  isolates  containing 
E. meleagrimitis and E. adenoides (and E. dispersa in the third study). At the end of the experiment 
(when the turkeys were 28 days old) the birds were killed and evaluated for intestinal lesion scores. 
The origin of the field isolates was France for study 1, Germany for study 2 and Belgium for study 3. 
In sensitivity study 1,
39 the zootechnical performance of the birds was similar until the turkeys reached 
23 days of age. The final mean body weight and feed-to-gain ratio in the IUC group (709 g/bird and 
2.01, respectively) were significantly  lower than in the IT group (771 g/bird and 1.82, respectively) 
and the UUC group (793 g/bird and 1.67 g/g, respectively). Oocyst excretion in 23-day-old turkeys 
was significantly lower in the IT group than in the IUC group for all Eimeria spp. and no excretion 
was observed in the UUC group. When the turkeys reached 28 days of age, oocyst excretion was low 
and similar in the IT and IUC groups. Some excretion was also observed in the UUC group. No 
significant differences were observed for lesion scores between the IT and IUC groups. 
                                                        
38 Supplementary information, February 2014/ Reference 3. 
39 Technical dossier/Section IV/Annex 8. Coxiril
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In sensitivity test 2,
40 no significant differences in body weight or feed intake were observed between 
groups at all time points. During the last week of the study, daily body weight gain in the UUC group 
(53 g/bird) was significantly higher than in the IT group (48 g/bird) and the IUC group (45 g/bird), and 
the feed-to-gain ratio in the UUC group (1.39) was significantly better than in the IUC group (1.80), 
whereas  feed-to-gain  ratio  of  the  IT  group  was  intermediate.  For  the  overall  study  period,  no 
significant differences in daily weight gain and feed-to-gain ratio among the groups were observed. 
The oocyst excretion rate on day 23 was significantly lower in the IT group than in the IUC group for 
E. meleagrimitis and E. dispersa, and no excretion was observed in the UUC group. On day 28, oocyst 
excretion was low and comparable between the IT and IUC groups. Some excretion was observed in 
the UUC group. No significant differences were observed for lesion scores between the IT and IUC 
groups. 
In  sensitivity  test  3,
41 no significant differences in body weight, weight gain  or  feed intake were 
observed between the IT group and the IUC group, but results were consistently better in the IT group. 
Lesions scores were not significantly lower in the IT group than in the IUC group, but they were 
consistently lower. No differences were seen in the OPG count between the IT and IUC groups. 
4.4.  Conclusions on efficacy 
Data published in the literature identify diclazuril from another source as an effective coccidiostat in 
turkeys for fattening at a dose range of 0.5 to 1.0 mg diclazuril/kg feed. Three floor pen studies and 
three  sensitivity  tests  with  an  intended  concentration  of  0.8 mg  diclazuril  from  Coxiril
®/kg  feed 
indicate that the additive has the potential to control coccidiosis from Eimeria spp. in turkeys for 
fattening. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
42  and  Good 
Manufacturing Practice. 
Field monitoring of Eimeria spp. resistance to diclazuril in turkeys for fattening should be undertaken, 
preferably during the later part of the period of authorisation. 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
Coxiril
® is considered safe for turkeys for fattening at the highest use level (1.2 mg diclazuril/kg feed) 
although  the  value  of  the  tolerance  study  is  somewhat  limited  due  to  weaknesses  in  the  design. 
However, none of the parameters measured showed an adverse effect of diclazuril at 12-fold the use 
level of diclazuril. Diclazuril has no substantial antibacterial activity. 
Diclazuril  from  Coxiril
®  is  considered toxicologically  equivalent to  the  other currently  authorised 
diclazuril. Since MRLs for diclazuril are not exceeded, the use of Coxiril
® at the highest proposed use 
level (1.2 mg diclazuril/kg complete feed) in turkeys for fattening is safe for the consumer. 
Coxiril
® is considered non-irritant to eyes and skin. It is not a potential skin sensitiser. User exposure 
to Coxiril
®, as a result of normal handling, is unlikely to cause respiratory or systemic toxicity. 
The  use  of  diclazuril  in  turkeys  for  fattening  at  the  high  use  level  does  not  pose  a  risk  to  the 
environment. 
                                                        
40 Technical dossier/Section IV/Annex 9. 
41 Technical dossier/Section IV/Annex 10. 
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Diclazuril from Coxiril
® has the potential to control coccidiosis in turkeys for fattening at a minimum 
concentration of 0.8 mg/kg complete feed. This conclusion is derived from literature data and from 
recent studies performed with Coxiril
®. 
RECOMMENDATIONS 
The specifications of Coxiril
® should refer to the substance-related impurities A to I, as listed in the 
European Pharmacopoeia (Ph. Eur. 7, 2011). 
The specifications of diclazuril in Coxiril
® should be amended by introducing a maximum content for 
the residues of a solvent used during the manufacturing process, compliant with the threshold set by 
the  International  Cooperation  on  Harmonisation  of  Technical  Requirements  for  Registration  of 
Veterinary Medicinal Products guidelines. 
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